Otsuka's Voyxact Shows Promise in Kidney Function Preservation, Yet Falls Short of Expectations
In a recent late-stage trial, Otsuka's kidney drug Voyxact demonstrated a reduction in the decline of kidney function over one year, but the results did not meet anticipated outcomes.
Editorial Staff
1 min read
Updated 5 days ago
Otsuka's drug, Voyxact, has shown some effectiveness in slowing the loss of kidney function in patients suffering from chronic autoimmune kidney disease during a one-year trial.
While the results indicate a positive impact on kidney function preservation, they were not as significant as researchers had hoped.
The findings highlight the ongoing challenges in developing effective treatments for chronic kidney conditions, as expectations for Voyxact's performance were not fully realized.